What are the predominant predictors of seizure relapse following discontinuation of anti-seizure medication in epileptic children?

被引:2
|
作者
Kanmaz, Seda [1 ]
Toprak, Dilara Ece [1 ]
Olculu, Cemile Busra [1 ]
Dokurel, Ipek [1 ]
Simsek, Erdem [1 ]
Serin, Hepsen Mine [1 ]
Yilmaz, Sanem [1 ]
Aktan, Gul [1 ]
Gokben, Sarenur [1 ]
Tekgul, Hasan [1 ]
机构
[1] Ege Univ, Med Fac, Dept Pediat, Div Child Neurol, TR-35100 Izmir, Turkiye
关键词
anti-seizure medication; ASM withdrawal; childhood; epilepsy; predictor; ANTIEPILEPTIC DRUGS; CHILDHOOD EPILEPSY; WITHDRAWAL; RISK; RECURRENCE; THERAPY;
D O I
10.1002/epd2.20019
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: The aim of the study was to identify the predominant predictors of seizure relapse following discontinuation of ASM in epileptic children. Methods: The study cohort consisted of 403 epileptic children who had a with-drawal process of ASM (monotherapy: 344; dual therapy or polytherapy: 59) after at least a 2- year seizure- free period. Patients were categorized if they had a well-defined epileptic syndrome. Epileptic children with ongoing ketogenic diet, vagal nerve stimulation, or surgery were excluded from the cohort due to the additional withdrawal process related to other therapy modalities. Results: The cohort's seizure relapse rate was 12.7% (51/403). The highest rates of seizure relapse were defined for genetic etiology at 25% and structural etiology at 14.9%. An epilepsy syndrome was defined in 183 of 403 children (45.4%). There was no difference in the seizure relapse rate between the subgroups of well-defined epileptic syndromes; 13.8% for self-limited focal epileptic syndromes, 11.7% for developmental and epileptic encephalopathies, and 7.1% for generalized epileptic syndromes. Five predictors were defined as the most powerful predictors of seizure relapse in univariate analysis: age at epilepsy diagnosis >2 years (hazard ratio [HR]: 1.480; 95% confidence interval [CI]: 1.134- 1.933), defined etiology (HR: 1.304; 95% CI: 1.003- 1.696), focal seizure (HR: 1.499; 95% CI: 1.209- 1.859), =3 months duration of the withdrawal process (HR: 1.654; 95% CI: 1.322- 2.070), and a history of neona-tal encephalopathy with or without seizures (HR: 3.140; 95% CI: 2.393- 4.122). In multivariate analysis, the main predictor of seizure relapse was a history of neonatal encephalopathy with or without seizures (HR: 2.823; 95% CI: 2.067- 3.854). Significance: The duration of seizure freedom before discontinuation of ASM was not a predominant risk factor for seizure relapse: 2- 3 years versus >3 years. The predictive values of five predictors of seizure relapse rate should be evaluated for patients with different epilepsy subgroups.
引用
收藏
页码:218 / 228
页数:11
相关论文
共 50 条
  • [31] Effect of Rapid Response EEG on Anti-Seizure Medication Usage
    Kurup, Deepika
    Davey, Zachary
    Hoang, Phuong
    Wu, Connie
    Werbaneth, Katherine
    Shah, Varun
    Hirsch, Karen G.
    Govindarajan, Prasanthi
    Meador, Kimford J.
    ANNALS OF NEUROLOGY, 2022, 92 : S88 - S89
  • [32] Developmental and Behavioral Consequences of Intrauterine Anti-Seizure Medication Exposure
    Yasguclukal, Miray Atacan
    Savas, Merve
    Acar, Zeynep
    Basoglu, Sezin
    Cokar, Ozlem
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2023, 60 (01): : 37 - 42
  • [33] Is Levetiracetam a Superior Anti-Seizure Medication in Pediatric Status Epilepticus?
    Anand S. Iyer
    Indian Pediatrics, 2023, 60 : 617 - 618
  • [34] Changes in seizure frequency and anti-seizure medication therapy during pregnancy and one year postpregnancy
    Du, Yanru
    Fang, Wenqiang
    Huang, Wenting
    Xu, Qi
    Gong, Jiaoni
    Xia, Niange
    Zhu, Zhenguo
    Wang, Xinshi
    Zheng, Rongyuan
    Xu, Huiqin
    EPILEPSY & BEHAVIOR, 2023, 144
  • [35] Anti-seizure medication prescription preferences: a Moroccan multicenter study
    Naji, Yahya
    Hrouch, Wafa
    Laadami, Sara
    Adali, Nawal
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [36] Availability, affordability, and quality of essential anti-seizure medication in Cambodia
    Sengxeu, Noudy
    Aon, Chanraksmey
    Dufat, Hanh
    Boumediene, Farid
    Chan, Samleng
    Ros, Sina
    Preux, Pierre-Marie
    Ratsimbazafy, Voa
    Jost, Jeremy
    EPILEPSIA OPEN, 2021, 6 (03) : 548 - 558
  • [37] A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication
    Strzelczyk, Adam
    Schubert-Bast, Susanne
    CNS DRUGS, 2022, 36 (03) : 217 - 237
  • [38] Seizure relapse following medication withdrawal in childhood epilepsy
    Hindley, Daniel
    Staniforth, Harriet
    ARCHIVES OF DISEASE IN CHILDHOOD, 2011, 96 (01) : 113 - 113
  • [39] Seizure control by adding on other anti-seizure medication on seizure during levetiracetam administration in patients with glioma-related epilepsy
    Hattori, Etsuko Yamamoto
    Arakawa, Yoshiki
    Mineharu, Yohei
    Furukawa, Keiko
    Terada, Yukinori
    Yamao, Yukihiro
    Tanji, Masahiro
    Kikuchi, Takayuki
    Miyamoto, Susumu
    BMC CANCER, 2023, 23 (01)
  • [40] Modelling developmental and epileptic encephalopathies in drosophila as a rapid in vivo assay system for anti-seizure medication response and neurodevelopment
    Toefflinger, E.
    Makridis, K.
    Heim, M.
    Kaindl, A. M.
    Owald, D.
    EPILEPSIA, 2024, 65 : 459 - 459